FDA-Labeled Indications for Chronic Weight Management As of early 2026, two medications carry FDA indications specifically for chronic weight management in adults: Wegovy (semaglutide 2.4 mg) approved 2021 Zepbound (tirzepatide) approved 2023 Liraglutide (Saxenda) is also approved for weight management but has been largely supplanted by the once-weekly options
Semaglutide is not approved or intended as a primary treatment for anxiety disorders
Ahead, Willowbrook, IL dermatologist Dr
3 Semaglutide: A More Potent GLP-1RA for Weight Loss Semaglutide (Wegovy ) has emerged as a more effective alternative to liraglutide for the treatment of adolescent obesity, demonstrating greater reductions in body weight and improvements in cardiometabolic parameters
However, a Cochrane review concluded that benefits are more evident in children over 6 months old and in populations with high risk of zinc deficiency, with limited evidence for benefit in well-nourished or younger children (Lazzerini and Wanzira, 2016)
Adding gas to the fire (literally) is a bad idea
.png)
